Comparing Atypical and Typical Antipsychotics in Schizophrenia Treatment
Author Information
Author(s): Ascher-Svanum Haya, Zhu Baojin, Faries Douglas, Landbloom Ron, Swartz Marvin, Swanson Jeff
Primary Institution: Lilly Research Laboratories, Eli Lilly and Company
Hypothesis
Time to medication discontinuation for any cause is longer for patients treated with atypical than typical antipsychotics, regardless of potency level.
Conclusion
Atypical antipsychotics lead to significantly longer time to medication discontinuation compared to typical antipsychotics in the treatment of schizophrenia.
Supporting Evidence
- Atypical antipsychotics had a mean time to discontinuation of 256.3 days compared to 197.2 days for typicals.
- Only clozapine and olanzapine showed significantly longer treatment duration compared to perphenazine.
- Results were confirmed by sensitivity analyses.
Takeaway
This study found that patients with schizophrenia stay on newer medications longer than older ones, which means the newer medications might work better for them.
Methodology
A large, observational, non-randomized, multisite study comparing time to all-cause medication discontinuation for atypical and typical antipsychotics over 1 year.
Potential Biases
Potential selection bias due to non-randomization and possible sponsor-related physician bias.
Limitations
The study's non-randomized design may introduce selection bias, and it did not assess reasons for medication discontinuation.
Participant Demographics
Participants were adults aged 18 and older, with a mean age of 40.8 years, predominantly male (59.2%) and White (51.9%).
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI for clozapine vs. all typicals: (2.39, 5.18)
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website